BIEL BioElectronics Corp.

BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain

BioElectronics Files FDA Application for Treatment of Musculoskeletal Pain

FREDERICK, MD, July 12, 2018 (GLOBE NEWSWIRE) -- BioElectronics Corporation (OTC PINK: BIEL), is pleased to announce that a Traditional 510(k) Premarket Notification for ActiPatch® was filed today with the U.S. Food and Drug Administration (FDA). The market clearance requested was “over-the-counter adjunctive use in the treatment of musculoskeletal pain”.

While ActiPatch is already FDA-cleared for adjunctive treatment of pain from knee osteoarthritis (25 million) and plantar fasciitis (2 million annually), expanded market clearance would allow additional products for the back (42 million), neck (19 million), hip (9 million), shoulder (11 million), carpal tunnel (12 million) and many other musculoskeletal complaints. Full details about the study can be found at the NIH’s clinical trials listing page: ().

The 510(k) was prepared by the R&D team comprising: Kenneth McLeod, Ph.D., Director of Clinical Science and Engineering Research, State University of New York at Binghamton and Richard Staelin, Ph.D., Gregory Mario and Jeremy Mario Professor, Duke University, Ian Rawe, Director of Clinical Research, BioElectronics and Sree Koneru, Ph.D., VP Product Development, BioElectronics. Dr. Koneru, who spearheaded the 510(k) effort, said, “We are confident with the strength of our data and overall application. Given the FDA’s prior knowledge of the data and prior clearances, we believe that the 510(k) will be processed in a timely manner.”

Keith Nalepka, VP of Sales/Marketing, remarked on the market opportunity: “An expanded market clearance will make ActiPatch available as a drug-free, safe, pain relief option for the 126 million Americans (one in two adults) who are suffering with musculoskeletal pain.”

About BioElectronics Corporation

BioElectronics Corporation is a leader in non-invasive electroceuticals and the maker of an industry leading family of disposable, drug-free, pain therapy devices: ActiPatch® Therapy, over-the-counter treatment for back pain and other musculoskeletal complaints; RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit 

Paul Knopick
9402623584
 
EN
12/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioElectronics Corp.

 PRESS RELEASE

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corpor...

Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru’s appointment, the Board will consist of three members, including Kelly Whelan, President of BioElectronics, and its Chairman, Richard Staelin, PhD. "We are honored to welcome Sree Koneru to the Board. Sree brings a rich depth of experience in medical device developm...

 PRESS RELEASE

BioElectronics Corporation's Chairman Updates Investors

BioElectronics Corporation's Chairman Updates Investors Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. Dear Shareholders, It has been a while since I provided an update on BioElectronics Corporation's activities. Below are some of the most significant. Current Medical (RecoveryRx) Sales Although our RecoveryRx product is well ac...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of a Canine Arthr...

BioElectronics Corporation Announces the Publication of a Canine Arthritis Study 96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via -- BioElectronics Corporation ( OTC: BIEL) a developer of medical technology products, announces the results and publication of a study investigating the efficacy of its FDA-cleared pulsed-shortwave-therapy (PSWT)device in initiating a systemic anti-inflammatory response to improve functionality of canines diagnosed with osteoarthritis. 96% of the treatment group showed ...

 PRESS RELEASE

BioElectronics Corporation Announces the Publication of Pilot Study Re...

BioElectronics Corporation Announces the Publication of Pilot Study Results Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating the treatment of phantom and residual limb pain using its pulsed shortwave therapy device. "Treating intractable postamputation pain with wearable, non-invasive, non-thermal, pulsed shortwave (radiofrequency) therapy: a randomized, double-ma...

 PRESS RELEASE

BioElectronics Chairman Updates Investors

BioElectronics Chairman Updates Investors Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via – BioElectronics Corporation ( OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin, PhD. The intent of this short update is to provide potential investors and current stockholders as much information as possible on the progress of our Company over these last three months and our future plans.  As I have mentioned many times, I believe our strategic m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch